Kirsten rat sarcoma viral oncogene (KRAS) G12D and pan-RAS inhibitors in pancreatic ductal adenocarcinoma: clinical progress and strategies to overcome resistance
Cancer Pathogenesis and Therapy · 2026-11
DOI: 10.1016/j.cpt.2026.11.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Pathogenesis and Therapy, 2026-11. Verfasst von Xiang Li und 3 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Li, X., Chen, Y., Zhang, X., & Bai, X. (2026). Kirsten rat sarcoma viral oncogene (KRAS) G12D and pan-RAS inhibitors in pancreatic ductal adenocarcinoma: clinical progress and strategies to overcome resistance. Cancer Pathogenesis and Therapy. https://doi.org/10.1016/j.cpt.2026.11.004
Vancouver
Li X, Chen Y, Zhang X, Bai X. Kirsten rat sarcoma viral oncogene (KRAS) G12D and pan-RAS inhibitors in pancreatic ductal adenocarcinoma: clinical progress and strategies to overcome resistance. Cancer Pathogenesis and Therapy. 2026. doi:10.1016/j.cpt.2026.11.004
BibTeX
@article{Li2026,
author = {Li, Xiang and Chen, Yiwen and Zhang, Xiaozhen and Bai, Xueli},
title = {Kirsten rat sarcoma viral oncogene (KRAS) G12D and pan-RAS inhibitors in pancreatic ductal adenocarcinoma: clinical progress and strategies to overcome resistance},
journal = {Cancer Pathogenesis and Therapy},
year = {2026},
doi = {10.1016/j.cpt.2026.11.004}
}
EUVIMED